Headline takeaways
- Adult obesity prevalence (BMI ≥30) reached ~16% globally in 2022 – exceeding 40% in the US, Saudi Arabia and several Pacific markets.
- Modern incretins finally cross the bariatric efficacy threshold – Zepbound (tirzepatide) 20.9% mean WL; retatrutide 24% in Phase II.
- ABI bottom-up: $15B (2024) → $92B (2030 Base) → $110B (2035). Constrained $60B (2030); Accelerated $129B (2030).
- Two innovators (Novo + Lilly) hold ~96% of 2024 revenue. CR2 falls to ~75% by 2030 as pipeline launches and biosimilars enter Asia.
- Patent cliffs reshape the market in waves – semaglutide LOE March 2026 in India / China / Brazil / Canada; US 2031–2033.
- The Technology section anchors on FDA Drugs@FDA – 8 approved drugs across 4+ mechanisms; 107+ pipeline programs.
- Investment thesis: Overweight innovators through 2027; rotate by 2028 into oral GLP-1, amylin combos, supply-chain enablers, and Asia-generics.
2030 by-region donut
Source: ABI Analytics bottom-up sizing.
ABI Analytics forecast: Global obesity-drug net revenue 2024 → 2035
Source: ABI Analytics bottom-up build (Section 9). Anchored on WHO GHO 2022 + sponsor 10-K disclosures + ICER white paper (April 2025).
Disease Overview & Global Epidemiology
Adult obesity prevalence – top-10 focus countries (WHO 2022)
Source: WHO Global Health Observatory, indicator NCD_BMI_30A – age-standardized adult obesity prevalence (BMI ≥30), 2022. ABI Analytics extract.
Long-run trend, 1990 → 2022
Source: WHO GHO long-run series.
Estimated global cost of obesity
Source: ICER (April 2025); OECD Health at a Glance; McKinsey Global Institute (2014); peer-reviewed literature.
Comorbidity burden
Obesity is causally implicated in:
• Type 2 diabetes – 90% of T2D adults are overweight/obese (BIO HPCD)
• Cardiovascular disease – SELECT 20% RR-reduction in 3-pt MACE (Wegovy)
• MASH / NASH – ESSENCE, SYNCHRONY-MASH-1 readouts
• Heart failure (HFpEF) – SUMMIT (tirzepatide)
• Obstructive sleep apnea – SURMOUNT-OSA (Zepbound 2024 label)
• Chronic kidney disease – FLOW (semaglutide)
• 13+ cancers (CDC, AICR)
• ~5M attributable deaths/year (Global Burden of Disease 2019)
Source: WHO GBD; peer-reviewed clinical literature.
Market Size & Forecast
Definition (callout)
Branded prescription chronic weight management drugs with FDA / EMA / equivalent regulatory approvals; OTC orlistat included; rare-genetic obesity drugs (Imcivree, Myalept) included. Excluded: off-label T2D-only label use of GLP-1 drugs, bariatric surgery and devices, digital-only behavioral programs, OTC herbals.
Annual TAM trajectory – Base scenario
2030 by-region donut
Mechanism mix shift (2024 → 2035)
Annual spend by region – Base scenario
Sizing Build – bottom-up TAM transparency table (Table 9-1)
| Step | Variable | 2024/25 | 2030 | 2035 | Source |
|---|---|---|---|---|---|
| 1 | Global adult population (M, 18+ yrs) | 5,648 | 6,031 | 6,323 | UN World Population Prospects 2024 |
| 2 | Adult obesity prevalence (age-std) | 16.2% | 17.8% | 19.4% | WHO GHO 2022; NCD-RisC trends |
| 3 | Adults with obesity (M) | 915 | 1,074 | 1,227 | Step 1 × Step 2 |
| 4 | Overweight + comorbidity uplift | +25% | +25% | +25% | ICER 2025; CDC NHANES; OECD |
| 5 | Total addressable population (M) | 1,144 | 1,343 | 1,534 | Step 3 × (1+ Step 4) |
| 6 | Care-seeking + diagnosis rate | 35% | 55% | 68% | CDC NHANES; OECD; ABI projection |
| 7 | Treatment-initiation rate | 9% | 30% | 46% | Sponsor 10-Ks; ABI projection |
| 8 | Persistence at 12 months | 40% | 52% | 58% | Cureus 2025 review; ABI projection |
| 9 | Effective treated population (M) | 3.5 | 36 | 75 | Computed at country bottom-up |
| 10 | Weighted net price ($/yr) | $4,300 | $2,500 | $1,500 | FDA WAC; ICER; payer formularies |
| 11 | GLOBAL TAM (Base, USD B) | $15B | $92B | $110B | Step 9 × Step 10 / 1000 – KEY OUTPUT |
Source: WHO GHO; UN World Population Prospects 2024; CDC NHANES; ICER (April 2025); FDA labels; sponsor 10-K disclosures; CareEdge Ratings (March 2026); ABI Analytics estimates.
Triangulation – bottom-up vs aggregated company revenues (Table 9-2)
| Source | 2024 obesity-franchise revenue | Notes |
|---|---|---|
| Novo Nordisk | $9.0B | Wegovy + Saxenda + minor |
| Eli Lilly | $5.8B | Zepbound (Mounjaro is T2D-coded, excluded) |
| Currax / Vivus / Roche / minor | $0.3B | Older agents – Qsymia / Contrave / Xenical |
| Imcivree (Rhythm) | $0.1B | Rare-genetic ultra-orphan |
| Indian co-marketers | $0.05B | Cipla–Yurpeak, Emcure–Poviztra (late-2025 launch) |
| Total disclosed obesity-franchise (FY24) | ~$15.2B | |
| ABI bottom-up (global, 2024) | $15.2B | See Sizing Build above |
| Reconciliation gap | ~$0.0B | Within rounding / definitions |
Source: Sponsor 10-Ks and annual reports FY2024; ABI Analytics bottom-up.
Competitive Dynamics
Concentration: ~96% of 2024 obesity-drug revenue with two innovators
Source: Sponsor 10-Ks and annual reports FY2024.
Top-15 global ranking – obesity-franchise revenue 2024
| # | Company | Country | HQ | Ticker | Total revenue | Obesity franchise | % of total | Description |
|---|---|---|---|---|---|---|---|---|
| 1 | Novo Nordisk | Denmark | Bagsvaerd | NVO / NOVO-B.CO | $41.1B | $9.00B | 21.9% | Innovator of liraglutide and semaglutide; Wegovy + Saxenda lead the obesity franchise |
| 2 | Eli Lilly | United States | Indianapolis | LLY | $45.0B | $5.80B | 12.9% | Innovator of tirzepatide (Zepbound); pipeline includes retatrutide, orforglipron, eloralintide |
| 3 | Cipla | India | Mumbai | CIPLA.NS | $3.3B | $0.10B | 3.0% | Yurpeak (tirzepatide) co-marketer with Lilly in India |
| 4 | Roche | Switzerland | Basel | ROG.SW | $65.3B | Pipeline-only | 0.0% | Pipeline only via Carmot acquisition (CT-388, CT-996) |
| 5 | Pfizer | United States | New York | PFE | $63.6B | Pipeline-only | 0.0% | Discontinued danuglipron 2025; pipeline pivot pending |
| 6 | Boehringer Ingelheim | Germany | Ingelheim | Private | $27.3B | Pipeline-only | 0.0% | Survodutide (with Zealand) Phase III |
| 7 | Zealand Pharma | Denmark | Copenhagen | ZEAL.CO | $0.2B | Pipeline-only | 0.0% | Petrelintide amylin lead; survodutide partner |
| 8 | Amgen | United States | Thousand Oaks | AMGN | $33.4B | Pipeline-only | 0.0% | MariTide (AMG133) GLP-1/GIPR antagonist Phase III |
| 9 | Innovent Biologics | China | Suzhou | 1801.HK | $1.2B | Pipeline-only | 0.0% | Mazdutide China-first dual agonist; Lilly partnered |
| 10 | Jiangsu Hengrui Pharma | China | Lianyungang | 600276.SS | $4.1B | Pipeline-only | 0.0% | HRS9531 GLP-1/GIP dual Phase III |
| 11 | Viking Therapeutics | United States | San Diego | VKTX | $0.0B | Pipeline-only | 0.0% | VK2735 GLP-1/GIP dual; oral and SC |
| 12 | Altimmune | United States | Gaithersburg | ALT | $0.0B | Pipeline-only | 0.0% | Pemvidutide (ALT-801) GLP-1/Glucagon Phase II/III |
| 13 | Structure Therapeutics | United States | San Francisco | GPCR | $0.0B | Pipeline-only | 0.0% | GSBR-1290 oral small-molecule GLP-1 |
| 14 | Sun Pharmaceutical | India | Mumbai | SUNPHARMA.NS | $5.7B | Pipeline-only | 0.0% | Semaglutide generic approved post 2026 LOE |
| 15 | Biocon | India | Bengaluru | BIOCON.NS | $1.8B | Pipeline-only | 0.0% | Liraglutide and semaglutide generics post-LOE |
Source: Sponsor 10-Ks, 20-Fs and annual reports FY2024.
Country Deep-Dives – Top 10
Top-10 country obesity-drug spend trajectories, 2024–2035 (Base, USD B)
Source: ABI Analytics bottom-up sizing.
Country snapshot table (sortable)
| Country | Adult pop (M) | Obesity prevalence | Addressable pop (M) | Treated 2024 (M) | Treated 2030 (M) | 2024 TAM | 2030 TAM | 2035 TAM |
|---|---|---|---|---|---|---|---|---|
| United States | 260 | 42.0% | 142 | 1.70 | 15.6 | $11.07B | $65.6B | $74.1B |
| China | 1110 | 8.3% | 115 | 0.09 | 3.5 | $0.22B | $3.8B | $4.8B |
| India | 950 | 7.3% | 87 | 0.05 | 1.7 | $0.08B | $0.7B | $1.0B |
| Brazil | 170 | 28.1% | 60 | 0.30 | 3.0 | $0.66B | $3.3B | $3.9B |
| Mexico | 95 | 36.0% | 43 | 0.21 | 1.7 | $0.51B | $2.2B | $2.6B |
| United Kingdom | 53 | 26.8% | 18 | 0.15 | 1.4 | $0.43B | $2.9B | $3.9B |
| Germany | 70 | 20.4% | 19 | 0.13 | 1.3 | $0.40B | $2.9B | $3.6B |
| Japan | 103 | 5.5% | 8 | 0.02 | 0.2 | $0.04B | $0.4B | $0.8B |
| Saudi Arabia & GCC | 45 | 38.0% | 21 | 0.13 | 1.3 | $0.45B | $2.9B | $3.7B |
| South Africa | 40 | 30.8% | 15 | 0.04 | 0.4 | $0.07B | $0.4B | $0.5B |
Drugs – Approved & Under Development
Primary source: https://www.fda.gov/drugs – Drugs@FDA, Orange Book, Purple Book, FDA labels. Cross-referenced with EMA EPAR, PMDA, NMPA, ClinicalTrials.gov, sponsor R&D pipelines.
Mechanism-of-action map – approved & pipeline obesity drugs
Source: FDA Drugs@FDA (approved); ClinicalTrials.gov + sponsor pipelines (development).
Table 7-1 – FDA-approved chronic weight management drugs (2025)
| Drug INN / Brand | Sponsor | FDA approval | Mechanism | Route | Indications on label | Mean WL vs pbo | WAC list/mo |
|---|---|---|---|---|---|---|---|
| Orlistat (Xenical / Alli) | Roche / GSK (OTC) | 1999 | Pancreatic lipase inhibitor | Oral | Chronic weight mgmt; OTC at 60mg | 4.0% | $100 |
| Phentermine-Topiramate (Qsymia) | Vivus / Currax Pharma | 2012 | Sympathomimetic + GABA modulator | Oral | Chronic weight mgmt; REMS | 8.0% | $200 |
| Naltrexone-Bupropion (Contrave) | Currax Pharma | 2014 | Opioid antagonist + DNRI | Oral | Chronic weight mgmt | 5.0% | $100 |
| Liraglutide (Saxenda) | Novo Nordisk | 2014 | GLP-1 receptor agonist | SC daily | Chronic weight mgmt; pediatric 12+ (2020) | 8.0% | $1,349 |
| Semaglutide (Wegovy) | Novo Nordisk | 2021 | GLP-1 receptor agonist | SC weekly | Chronic weight mgmt; CV-risk reduction (SELECT, 2024) | 14.9% | $1,349 |
| Tirzepatide (Zepbound) | Eli Lilly | 2023 | Dual GIP/GLP-1 agonist | SC weekly | Chronic weight mgmt; OSA in obesity (2024) | 20.9% | $1,086 |
| Setmelanotide (Imcivree) | Rhythm Pharmaceuticals | 2020 | MC4R agonist | SC daily | POMC/PCSK1/LEPR/Bardet-Biedl deficiency obesity | 12.0% | $25,000 |
| Metreleptin (Myalept) | Chiesi (formerly Aegerion) | 2014 | Leptin analog | SC daily | Generalized lipodystrophy | 0.0% | $70,000 |
Source: FDA Drugs@FDA, FDA labels, sponsor disclosures. Mean weight loss is from pivotal trials at 56–72 weeks vs placebo.
Table 7-2 – High-priority pipeline drugs (Phase II / III / Filed)
| Drug INN/code | Sponsor | Mechanism | Phase | Lead NCT | Anticipated launch | Lead indication | ABI view |
|---|---|---|---|---|---|---|---|
| Retatrutide (LY3437943) | Eli Lilly | GIP/GLP-1/Glucagon triple agonist | Phase III | NCT05929066 / NCT05882045 | H2 2026 / 2027 | Obesity (TRIUMPH program) | Best-in-class efficacy potential (~24% WL Phase II); will reset bar |
| Orforglipron (LY3502970) | Eli Lilly | Oral non-peptide GLP-1 | Phase III | NCT05869903 (ATTAIN-1) / NCT05803421 | H2 2026 | Obesity / T2D | Oral disrupts injection paradigm; ~7-15% WL based on ATTAIN-1 readout May 2025 |
| CagriSema (cagrilintide+semaglutide) | Novo Nordisk | GLP-1 + Amylin combo | Phase III | NCT05567796 (REDEFINE-1) | 2026 | Obesity | Below-expectation Dec-24 readout (~22.7% WL vs 25% guidance) – share rotated to Lilly |
| Survodutide (BI 456906) | Boehringer Ingelheim / Zealand Pharma | GLP-1 / Glucagon dual | Phase III | NCT06066515 / NCT06077864 | H2 2027 | Obesity / MASH | MASH readout 2024 positive; obesity Phase III ongoing |
| Mazdutide (IBI362) | Innovent / Eli Lilly (China) | GLP-1 / Glucagon dual | Filed (China) | NCT05607680 (GLORY-1) | H2 2025 China | Obesity | China-first launch; NMPA review; ~15% WL at 6mg |
| Bimagrumab + semaglutide | Eli Lilly (via Versanis) | Activin Type II receptor mAb (anti-myostatin) + GLP-1 | Phase IIb | NCT05616013 (BELIEVE) | 2027+ | Obesity (lean mass preservation) | Lean-mass thesis; combo with semaglutide |
| Amycretin | Novo Nordisk | Single-molecule GLP-1 + Amylin (oral and SC) | Phase II | NCT05669693 | 2028+ | Obesity | Phase I oral 13.1% WL @ 12 weeks; Novo response to Lilly |
| Petrelintide (ZP8396) | Zealand Pharma | Long-acting amylin analog | Phase II/III | NCT06709963 | 2027-28 | Obesity | Best-tolerated profile potential; combo candidate |
| MariTide (AMG133) | Amgen | GLP-1 / GIPR antagonist mAb | Phase III | NCT05669599 | Q4 2030 | Obesity | Monthly dosing thesis; mid-2024 Phase II ~20% WL but durability questions |
| VK2735 | Viking Therapeutics | GLP-1 / GIP dual (SC and oral) | Phase II / III | NCT06068946 | 2028+ | Obesity | Acquisition target; 14.7% WL @ 13 wks Phase II |
| Pemvidutide (ALT-801) | Altimmune | GLP-1 / Glucagon dual | Phase II/III | NCT04881760 (MOMENTUM) | 2027+ | Obesity / MASH | 15.6% WL at 2.4mg over 48 weeks |
| Ecnoglutide (XW003) | Sciwind Biosciences | GLP-1 RA | Phase III | NCT05813795 | 2026+ (China) | Obesity / T2D | China generic-class entry |
| HRS9531 | Jiangsu Hengrui | GLP-1 / GIP dual | Phase III | NCT06396429 | Q4 2026 China | Obesity | China-first dual agonist |
| Eloralintide | Eli Lilly | Long-acting amylin analog | Phase II | – | 2028+ | Obesity | Lilly amylin program; complement to retatrutide |
| CT-388 | Carmot / Roche | GLP-1 / GIP dual | Phase II | NCT04834804 | 2028+ | Obesity / T2D | Roche acquisition rationale; Phase I 18.8% WL @ 24 wks |
| CT-996 | Carmot / Roche | Oral GLP-1 | Phase II | NCT06262126 | 2028+ | Obesity | Roche oral entry |
| Danuglipron | Pfizer | Oral non-peptide GLP-1 | DISCONTINUED 2025 | NCT05295875 | N/A | Obesity | Discontinued April 2025 due to elevated LFTs in DILI signal – Pfizer pivot pending |
| Monlunabant (INV-202) | Novo Nordisk (via Inversago) | CB1 inverse agonist (peripheral) | Phase II | NCT05891834 | 2028+ | Obesity / DKD | Peripheral CB1; rimonabant-class but improved |
| Tesofensine | Saniona / Medix | Triple monoamine reuptake inhibitor | Approved Mexico (2023) | NCT00394667 | Approved Mex; FDA path uncertain | Obesity | Mexico launch 2023; CV safety questions remain for FDA |
Source: ClinicalTrials.gov, sponsor R&D pipelines, FDA Drugs@FDA, IQVIA Pipeline Link Sept 2024, Melson et al. IJO 2025. ABI Analytics compilation.
Efficacy / tolerability landscape
Bubble = ABI 2030 peak-sales estimate.
Pipeline density by mechanism & phase
Source: IQVIA Pipeline Link via "Obesity key pipeline developments" (September 2024).
Patent / LOE timeline
Source: FDA Orange Book, EPO, Indian Patent Office, INPI Brazil, NMPA, JPO, sponsor 10-Ks, CareEdge Ratings (March 2026).
Cross-Cutting Thematic Deep-Dives
Theme 1 – The supply ramp through 2028
Wegovy off shortage list Feb 2025; Zepbound Oct 2024. Lilly's Concord NC, Lebanon IN and RTP capex through 2027 will roughly triple internal Mounjaro/Zepbound supply. Novo–Catalent acquisition (Dec 2024, $16.5B) added critical fill-finish.
Theme 2 – Compounded GLP-1 end-game
503A and 503B compounding pharmacies fueled $2–4B of GLP-1 dispensing 2023–24. FDA shortage-list removal deauthorized large-scale compounding. April 2025 federal court ruling upheld FDA authority. Compounded share <5% by end-2025.
Theme 3 – Oral GLP-1 changes prescribing
Orforglipron's H2 2026 expected approval inaugurates the oral GLP-1 era. Lower efficacy (7–15% WL) balanced by simpler adoption, no needle barrier, lower price. Adds +20% to PCP-reachable addressable population by 2027.
Theme 4 – Cardiometabolic label expansion
Each new label widens the reimbursable pool. SELECT (CV, 2024); SURMOUNT-OSA (2024); ESSENCE (MASH); SUMMIT (HFpEF); FLOW (CKD). By 2030 the average obesity-treated patient will carry 2.5+ reimbursable comorbidity codes.
Theme 5 – Pricing & access – Medicare, ICER, PBM
Medicare obesity coverage decision = largest remaining policy variable. CMS Nov-2024 expansion proposal rescinded Feb 2025. ICER (Apr 2025) found semaglutide / tirzepatide net prices already meet $/QALY thresholds. Gross-to-net 50–60% by 2028.
Theme 6 – Biosimilars in Asia, then US
Liraglutide off-patent. Semaglutide LOE March 2026 in India / China / Brazil / Canada – generic supply at $40–80/mo. US semaglutide LOE 2031–33 contingent on litigation. Tirzepatide US 2036.
Theme 7 – Digital / telehealth distribution
Hims, Ro, Noom, WeightWatchers (Sequence), Embla, Numan, Boots online – built scalable cash-pay GLP-1 distribution. Self-pay channel ~$4B in 2024 (Stifel). 5–10 ppt EBITDA-margin uplift opportunity.
Theme 8 – Equity & global access
2026 LOEs unlock generic semaglutide at $40–80/mo (5–10× cheaper). India ~20% of global generics by volume. WHO and World Bank early discussions on GAVI-style access mechanisms.
Forecasts & Cumulative Spend
Annual obesity-drug spend by region
Source: ABI Analytics bottom-up sizing.
Mechanism mix 2024 → 2030 → 2035
Source: ABI Analytics estimates.
2030 Base TAM by region – donut
Investability Framework
Where to play, by fund type and time horizon
Risk Register
Sources & References
Primary sources (source-policy-compliant)
- WHO Global Health Observatory – adult obesity prevalence (NCD_BMI_30A) 2022; https://www.who.int/data/gho
- FDA Drugs@FDA, Orange Book, Purple Book, FDA labels – https://www.fda.gov/drugs
- FDA Drug Shortages – Wegovy removed Feb 2025; Zepbound Oct 2024
- Sponsor 10-K and 20-F annual reports FY2024 – Novo Nordisk, Eli Lilly, Roche, Pfizer, Boehringer Ingelheim, Amgen, Innovent, Hengrui, Cipla, Sun, Biocon
- ICER White Paper – "Affordable Access to GLP-1 Obesity Medications" – April 9, 2025 (Pearson SD, Whaley CM, Emond SK)
- CareEdge Ratings – "Indian GLP-1 Market to Expand 5x in Next 5 Years" – March 10, 2026
- IQVIA Pipeline Link – "Obesity key pipeline developments and clinical trial insights" – September 2024
- BIO HPCD Vol III – Type 2 Diabetes and Obesity Report – 2024 (David Thomas CFA, Chad Wessel)
- Stifel – Obesity Drug Market Update (equity research) – July 9, 2025
- Cureus 17(11):e96713 – Manoria PC, "The Obesity Drug Revolution: New Frontiers in Pharmacotherapy" – November 2025; DOI 10.7759/cureus.96713
- Int J Obes 49:433–451 – Melson E et al., "What is the pipeline for future medications for obesity?" – 2025; DOI 10.1038/s41366-024-01473-y
- UN World Population Prospects – 2024 Revision; https://population.un.org/wpp/
- OECD Health Statistics 2024 – Health at a Glance series
- CDC NHANES – 1960–2022 series
- NCD-RisC – https://ncdrisc.org/
- NICE Technology Appraisals – TA664 (Saxenda), TA875 (Wegovy), TA1026 (Mounjaro)
- EMA EPAR – Saxenda, Wegovy, Mounjaro / Zepbound
- Trial registry – ClinicalTrials.gov
- Patent offices – USPTO, EPO Espacenet, Indian Patent Office, INPI Brazil, China NIPA, Japan JPO